AZN) upon the dosing of the first patient in AstraZeneca’s Phase 3 trial of rilvegostomig, a PD-1TIGIT bispecific antibody. This milestone payment is part of a license agreement between Compugen and AstraZeneca, where AstraZeneca has the exclusive rights to use Compugen’s anti-TIGIT antibody, COM902, for the development of bispecific and multispecific antibody products.\n\nThe Phase 3 trial, known as ARTEMIDE-Bil01, is expected to enroll 750 subjects in more than 20 countries with biliary tract cancer. These subjects will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent. This advancement of rilvegostomig into Phase 3 by AstraZeneca, a global leader in oncology, is a significant step towards exploring the potential of this bispecific antibody.\n\nCompugen’s President and CEO, Anat Cohen-Dayag, Ph.D., expressed her delight in the progress of the rilvegostomig clinical program and the commitment shown by AstraZeneca in exploring the potential of this bispecific antibody. She also highlighted the progress of the Phase 1 and 2 trials in additional indications, which further solidifies the company’s position as a pioneer in computational target discovery.\n\nThe license agreement between Compugen and AstraZeneca was signed in 2018, and Compugen has already received a $10 million upfront payment and an additional $15.5 million in milestone payments to date. The company is eligible to receive up to an aggregate milestone amount of $200 million, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen’s monospecific antibodies that bind to TIGIT, the company will also receive additional milestones and royalties.\n\nCompugen is a clinical-stage therapeutic discovery and development company that utilizes its predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has two proprietary product candidates, COM701 and COM902, and a clinical-stage partnered program, rilvegostomig, which is in Phase 3 development by AstraZeneca.\n\nIn a the dosing of the first patient in AstraZeneca’s Phase 3 trial of rilvegostomig marks a significant milestone for Compugen and its partnership with AstraZeneca.”